Clinical Pathways promote evidence-based, safe, and high-value care for patients by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by a methodical review of available evidence and consensus among committee members.
The Tumor Lysis Syndrome (TLS) synopsis provides a high-level overview of the care standards employed for this Clinical Pathway.
Algorithms associated with this Clinical Pathway:
Inclusion and exclusion criteria
- Patients with suspected or newly diagnosed or newly relapsed malignancy should be screened for TLS.
- Non oncologic diagnoses associated with hyperuricemia (i.e., hemolytic uremic syndrome, chronic renal failure, etc.).
Committee members involved in the development:
- N. Wood, DO | Department of Hematology, Oncology, and Blood and Marrow Transplantation | Committee Chair
- K. August, MD, MS | Department of Hematology, Oncology and Blood and Marrow Transplantation | Committee member
- J. Rilinger, MD | Department of Critical Care Medicine | Committee member
- A. Hadley, MD | Department of Emergency Medicine | Committee member
- M. Haywood, DO | Department of Emergency Medicine | Committee member
- T. Glenski, MD, MSHA, FASA | Department of Anesthesiology and Department of Evidence Based Practice | Committee member
- J. A. Bartlett, PhD, RN | Department of Evidence Based Practice | Committee member
- Finalized date: 08/03/22
- Next expected revision date: 08/25
Concerns with content
If you have any questions regarding this content or identify a broken link, please email firstname.lastname@example.org.